Mackenzie Financial Corp Lowers Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mackenzie Financial Corp reduced its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 28.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,262 shares of the biotechnology company's stock after selling 9,238 shares during the period. Mackenzie Financial Corp's holdings in Sarepta Therapeutics were worth $2,828,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Capital International Investors increased its position in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Norges Bank purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $126,315,000. Farallon Capital Management LLC increased its position in shares of Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after purchasing an additional 285,100 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $30,398,000. Finally, Summit Partners Public Asset Management LLC increased its position in shares of Sarepta Therapeutics by 174.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 379,150 shares of the biotechnology company's stock valued at $46,101,000 after purchasing an additional 241,032 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

SRPT stock traded down $0.89 on Friday, reaching $37.72. 3,085,574 shares of the company's stock were exchanged, compared to its average volume of 1,734,484. The stock has a fifty day moving average of $50.84 and a 200-day moving average of $91.78. Sarepta Therapeutics, Inc. has a twelve month low of $34.10 and a twelve month high of $173.25. The firm has a market cap of $3.71 billion, a PE ratio of 30.18 and a beta of 0.85. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter last year, the business earned $0.73 EPS. The firm's revenue for the quarter was up 80.2% on a year-over-year basis. As a group, equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 7.70% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Scotiabank lowered their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a report on Thursday, March 20th. Needham & Company LLC lowered their target price on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Guggenheim lowered their target price on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Evercore ISI downgraded Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price target on the stock. in a research note on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price objective on Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.61.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.